Date: 2013-03-12
Type of information: Licensing agreement
Compound: kinase inhibitor for the treatment of metastatic cancer
Company: the Max Planck Institute of Biochemistry (MPIB) (Germany) The Lead Discovery Center (LDC) (Germany) Qurient (South Korea)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: The lead compound belongs to a family of highly selective Axl kinase inhibitors that was jointly developed by LDC and Max-Planck researchers around Prof. Axel Ullrich at MPIB. Together they have shown that the new Axl kinase inhibitor interferes with key mechanisms of metastasis formation and significantly reduces the number of metastases in-vivo. The project originally emerged from a collaboration of MPIB with Vichem Chemie Research Ltd.
Disease:
Details: * On March 12, 2013, the Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide, exclusive rights to a new kinase inhibitor for the treatment of metastatic cancer. During the coming year, Qurient, LDC and MPIB will work closely together to ensure a smooth transition of the project into preclinical and clinical development at Qurient. The company plans to continue the project at least to clinical proof-of-concept before sublicensing it to a partner for further development and marketing.
Financial terms: Under the terms of the agreement, LDC and MPIB will receive an upfront payment as well as milestone and royalty payments, in line with the project’s progress.
Latest news:
